Niagen Bioscience (NASDAQ:NAGE) Price Target Raised to $16.00

Niagen Bioscience (NASDAQ:NAGE - Free Report) had its price objective hoisted by Canaccord Genuity Group from $13.00 to $16.00 in a research note released on Tuesday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other equities analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Niagen Bioscience from a "strong-buy" rating to a "buy" rating in a report on Friday, June 6th. Roth Capital reissued a "buy" rating and set a $23.00 price objective (up previously from $10.00) on shares of Niagen Bioscience in a report on Friday, June 6th.

Niagen Bioscience Stock Down 3.6%

NAGE stock traded down $0.51 on Tuesday, reaching $13.63. 879,867 shares of the company's stock were exchanged, compared to its average volume of 858,693. The stock has a fifty day moving average of $9.25 and a 200-day moving average of $7.12. The firm has a market cap of $1.07 billion, a PE ratio of 80.18 and a beta of 2.08. Niagen Bioscience has a twelve month low of $2.31 and a twelve month high of $14.49.

Niagen Bioscience Company Profile

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.